1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
2
|
The Lancet Gastroenterology Hepatology, .
Colorectal cancer screening: Is earlier better? Lancet
Gastroenterol Hepatol. 3:5192018. View Article : Google Scholar : PubMed/NCBI
|
3
|
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM
and Wallace MB: Colorectal cancer. Lancet. 394:1467–1480. 2019.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Lai M, Liu G, Li R, Bai H, Zhao J, Xiao P
and Mei J: Hsa_circ_0079662 induces the resistance mechanism of the
chemotherapy drug oxaliplatin through the TNF-α pathway in human
colon cancer. J Cell Mol Med. 24:5021–5027. 2020. View Article : Google Scholar : PubMed/NCBI
|
5
|
Zhou Y, Zhang J, Wang K, Han W, Wang X,
Gao M, Wang Z, Sun Y, Yan H, Zhang H, et al: Quercetin overcomes
colon cancer cells resistance to chemotherapy by inhibiting solute
carrier family 1, member 5 transporter. Eur J Pharmacol.
881:1731852020. View Article : Google Scholar : PubMed/NCBI
|
6
|
Meister G and Tuschl T: Mechanisms of gene
silencing by double-stranded RNA. Nature. 431:343–349. 2004.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Garofalo M and Croce CM: MicroRNAs: Master
regulators as potential therapeutics in cancer. Annu Rev Pharmacol
Toxicol. 51:25–43. 2011. View Article : Google Scholar : PubMed/NCBI
|
8
|
Xie Y, Tobin LA, Camps J, Wangsa D, Yang
J, Rao M, Witasp E, Awad KS, Yoo N, Ried T and Kwong KF:
MicroRNA-24 regulates XIAP to reduce the apoptosis threshold in
cancer cells. Oncogene. 32:2442–2451. 2013. View Article : Google Scholar : PubMed/NCBI
|
9
|
Yamanaka S, Campbell NR, An F, Kuo SC,
Potter JJ, Mezey E, Maitra A and Selaru FM: Coordinated effects of
microRNA-494 induce G2/M arrest in human
cholangiocarcinoma. Cell Cycle. 11:2729–2738. 2012. View Article : Google Scholar : PubMed/NCBI
|
10
|
Zhu H, Wu H, Liu X, Evans BR, Medina DJ,
Liu CG and Yang JM: Role of MicroRNA miR-27a and miR-451 in the
regulation of MDR1/P-glycoprotein expression in human cancer cells.
Biochem Pharmacol. 76:582–588. 2008. View Article : Google Scholar : PubMed/NCBI
|
11
|
D'Angelo E, Vicentini C, Agostini M, Kiss
A, Baffa R, Scarpa A and Fassan M: MicroRNAs as tools and effectors
for patient treatment in gastrointestinal carcinogenesis. Curr Drug
Targets. 16:383–392. 2015. View Article : Google Scholar
|
12
|
D'Angelo E, Zanon C, Sensi F, Digito M,
Rugge M, Fassan M, Scarpa M, Pucciarelli S, Nitti D and Agostini M:
MiR-194 as predictive biomarker of responsiveness to neoadjuvant
chemoradiotherapy in patients with locally advanced rectal
adenocarcinoma. J Clin Pathol. 71:344–350. 2018. View Article : Google Scholar
|
13
|
Gao C, Zhou C, Zhuang J, Liu L, Liu C, Li
H, Liu G, Wei J and Sun C: MicroRNA expression in cervical cancer:
Novel diagnostic and prognostic biomarkers. J Cell Biochem.
119:7080–7090. 2018. View Article : Google Scholar : PubMed/NCBI
|
14
|
Zhao L, Ni X, Zhao L, Zhang Y, Jin D, Yin
W, Wang D and Zhang W: MiroRNA-188 Acts as tumor suppressor in
Non-Small-Cell Lung cancer by Targeting MAP3K3. Mol Pharm.
15:1682–1689. 2018. View Article : Google Scholar : PubMed/NCBI
|
15
|
Peng Y, Shen X, Jiang H, Chen Z, Wu J, Zhu
Y, Zhou Y and Li J: MiR-188-5p suppresses gastric cancer cell
proliferation and invasion via Targeting ZFP91. Oncol Res.
27:65–71. 2018. View Article : Google Scholar : PubMed/NCBI
|
16
|
Li N, Shi H, Zhang L, Li X, Gao L, Zhang
G, Shi Y and Guo S: MiR-188 inhibits glioma cell proliferation and
cell cycle progression through targeting β-Catenin. Oncol Res.
26:785–794. 2018. View Article : Google Scholar : PubMed/NCBI
|
17
|
Pichler M, Stiegelbauer V,
Vychytilova-Faltejskova P, Ivan C, Ling H, Winter E, Zhang X,
Goblirsch M, Wulf-Goldenberg A, Ohtsuka M, et al: Genome-Wide miRNA
Analysis Identifies miR-188-3p as a novel prognostic marker and
molecular factor involved in colorectal carcinogenesis. Clin Cancer
Res. 23:1323–1333. 2017. View Article : Google Scholar : PubMed/NCBI
|
18
|
Wang L and Liu H: MicroRNA-188 is
downregulated in oral squamous cell carcinoma and inhibits
proliferation and invasion by targeting SIX1. Tumour Biol.
37:4105–4113. 2016. View Article : Google Scholar : PubMed/NCBI
|
19
|
Fang F, Chang RM, Yu L, Lei X, Xiao S,
Yang H and Yang LY: MicroRNA-188-5p suppresses tumor cell
proliferation and metastasis by directly targeting FGF5 in
hepatocellular carcinoma. J Hepatol. 63:874–885. 2015. View Article : Google Scholar : PubMed/NCBI
|
20
|
Zhang H, Qi S, Zhang T, Wang A, Liu R, Guo
J, Wang Y and Xu Y: MiR-188-5p inhibits tumour growth and
metastasis in prostate cancer by repressing LAPTM4B expression.
Oncotarget. 6:6092–6104. 2015. View Article : Google Scholar : PubMed/NCBI
|
21
|
Jinlong S, Lin F, Yonghui L, Li Y and
Weidong W: Identification of let-7a-2-3p or/and miR-188-5p as
prognostic biomarkers in cytogenetically normal acute myeloid
leukemia. PLoS One. 10:e01180992015. View Article : Google Scholar : PubMed/NCBI
|
22
|
Della Vittoria Scarpati G, Falcetta F,
Carlomagno C, Ubezio P, Marchini S, De Stefano A, Singh VK,
D'Incalci M, De Placido S and Pepe S: A specific miRNA signature
correlates with complete pathological response to neoadjuvant
chemoradiotherapy in locally advanced rectal cancer. Int J Radiat
Oncol Biol Phys. 83:1113–1119. 2012. View Article : Google Scholar : PubMed/NCBI
|
23
|
Pamonsinlapatham P, Hadj-Slimane R,
Lepelletier Y, Allain B, Toccafondi M, Garbay C and Raynaud F:
p120-Ras GTPase activating protein (RasGAP): A multi-interacting
protein in downstream signaling. Biochimie. 91:320–328. 2009.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Yang XY, Guan M, Vigil D, Der CJ, Lowy DR
and Popescu NC: p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor
protein and inhibits its RhoA GTPase and growth-suppressing
activities. Oncogene. 28:1401–1409. 2009. View Article : Google Scholar : PubMed/NCBI
|
25
|
Calvisi DF, Ladu S, Conner EA, Seo D,
Hsieh JT, Factor VM and Thorgeirsson SS: Inactivation of Ras
GTPase-activating proteins promotes unrestrained activity of
wild-type Ras in human liver cancer. J Hepatol. 54:311–319. 2011.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Mai A, Veltel S, Pellinen T, Padzik A,
Coffey E, Marjomäki V and Ivaska J: Competitive binding of Rab21
and p120RasGAP to integrins regulates receptor traffic and
migration. J Cell Biol. 194:291–306. 2011. View Article : Google Scholar : PubMed/NCBI
|
27
|
Sun D, Yu F, Ma Y, Zhao R, Chen X, Zhu J,
Zhang CY, Chen J and Zhang J: MicroRNA-31 activates the RAS pathway
and functions as an oncogenic MicroRNA in human colorectal cancer
by repressing RAS p21 GTPase activating protein 1 (RASA1). J Biol
Chem. 288:9508–9518. 2013. View Article : Google Scholar : PubMed/NCBI
|
28
|
Anand S, Majeti BK, Acevedo LM, Murphy EA,
Mukthavaram R, Scheppke L, Huang M, Shields DJ, Lindquist JN,
Lapinski PE, et al: MicroRNA-132-mediated loss of p120RasGAP
activates the endothelium to facilitate pathological angiogenesis.
Nat Med. 16:909–914. 2010. View Article : Google Scholar : PubMed/NCBI
|
29
|
Organ SL, Hai J, Radulovich N, Marshall
CB, Leung L, Sasazuki T, Shirasawa S, Zhu CQ, Navab R, Ikura M and
Tsao MS: p120RasGAP is a mediator of rho pathway activation and
tumorigenicity in the DLD1 colorectal cancer cell line. PLoS One.
9:e861032014. View Article : Google Scholar : PubMed/NCBI
|
30
|
Sharma SB, Lin CC, Farrugia MK, McLaughlin
SL, Ellis EJ, Brundage KM, Salkeni MA and Ruppert JM: MicroRNAs 206
and 21 cooperate to promote RAS-extracellular signal-regulated
kinase signaling by suppressing the translation of RASA1 and
SPRED1. Mol Cell Biol. 34:4143–4164. 2014. View Article : Google Scholar : PubMed/NCBI
|
31
|
Liu Y, Liu T, Sun Q, Niu M, Jiang Y and
Pang D: Downregulation of Ras GTPaseactivating protein 1 is
associated with poor survival of breast invasive ductal carcinoma
patients. Oncol Rep. 33:119–124. 2015. View Article : Google Scholar : PubMed/NCBI
|
32
|
Li Y, Qiu C, Tu J, Geng B, Yang J, Jiang T
and Cui Q: HMDD v2.0: A database for experimentally supported human
microRNA and disease associations. Nucleic Acids Res.
42:D1070–D1074. 2014. View Article : Google Scholar : PubMed/NCBI
|
33
|
Siderovski DP and Willard FS: The GAPs,
GEFs, and GDIs of heterotrimeric G-protein alpha subunits. Int J
Biol Sci. 1:51–66. 2005. View Article : Google Scholar : PubMed/NCBI
|
34
|
Gong B, Liu WW, Nie WJ, Li DF, Xie ZJ, Liu
C, Liu YH, Mei P and Li ZJ: MiR-21/RASA1 axis affects malignancy of
colon cancer cells via RAS pathways. World J Gastroenterol.
21:1488–1497. 2015. View Article : Google Scholar : PubMed/NCBI
|
35
|
Sun D, Wang C, Long S, Ma Y, Guo Y, Huang
Z, Chen X, Zhang C, Chen J and Zhang J: C/EBP-β-activated
microRNA-223 promotes tumour growth through targeting RASA1 in
human colorectal cancer. Br J Cancer. 112:1491–1500. 2015.
View Article : Google Scholar : PubMed/NCBI
|
36
|
Lu Y, Yang H, Yuan L, Liu G, Zhang C, Hong
M, Liu Y, Zhou M, Chen F and Li X: Overexpression of miR-335
confers cell proliferation and tumour growth to colorectal
carcinoma cells. Mol Cell Biochem. 412:235–245. 2016. View Article : Google Scholar : PubMed/NCBI
|
37
|
Zhang L, Zhan X, Yan D and Wang Z:
Circulating MicroRNA-21 is involved in lymph node metastasis in
cervical cancer by targeting RASA1. Int J Gynecol Cancer.
26:810–816. 2016. View Article : Google Scholar : PubMed/NCBI
|
38
|
Zhu YJ, Xu B and Xia W: Hsa-mir-182
downregulates RASA1 and suppresses lung squamous cell carcinoma
cell proliferation. Clin Lab. 60:155–159. 2014.PubMed/NCBI
|
39
|
Yan S, Yue Y, Wang J, Li W, Sun M, Gu C
and Zeng L: LINC00668 promotes tumorigenesis and progression
through sponging miR-188-5p and regulating USP47 in colorectal
cancer. Eur J Pharmacol. 858:1724642019. View Article : Google Scholar : PubMed/NCBI
|
40
|
Wu J, Chen Z, Liu W, Zhang Y, Feng W, Yuan
Y, Ye J, Wang L, Cai S, He Y, et al: MicroRNA-188-5p targeting
Forkhead Box L1 promotes colorectal cancer progression via
activating Wnt/β-catenin signaling. Oncol Res. Nov 23–2020.(Epub
ahead of print). View Article : Google Scholar
|
41
|
Wu J, Lv Q, He J, Zhang H, Mei X, Cui K,
Huang N, Xie W, Xu N and Zhang Y: MicroRNA-188 suppresses G1/S
transition by targeting multiple cyclin/CDK complexes. Cell Commun
Signal. 12:662014. View Article : Google Scholar : PubMed/NCBI
|
42
|
Chen YL, Huang WC, Yao HL, Chen PM, Lin
PY, Feng FY and Chu PY: Down-regulation of RASA1 is associated with
poor prognosis in human hepatocellular carcinoma. Anticancer Res.
37:781–785. 2017. View Article : Google Scholar : PubMed/NCBI
|
43
|
Hayashi T, Desmeules P, Smith RS, Drilon
A, Somwar R and Ladanyi M: RASA1 and NF1 are preferentially
Co-mutated and define a distinct genetic subset of
smoking-associated non-small cell lung carcinomas sensitive to MEK
inhibition. Clin Cancer Res. 24:1436–1447. 2018. View Article : Google Scholar : PubMed/NCBI
|
44
|
Suarez-Cabrera C, Quintana RM, Bravo A,
Casanova ML, Page A, Alameda JP, Paramio JM, Maroto A, Salamanca J,
Dupuy AJ, et al: A Transposon-based analysis reveals RASA1 Is
involved in triple-negative breast cancer. Cancer Res.
77:1357–1368. 2017. View Article : Google Scholar : PubMed/NCBI
|
45
|
Sung H, Kanchi KL, Wang X, Hill KS,
Messina JL, Lee JH, Kim Y, Dees ND, Ding L, Teer JK, et al:
Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras
activation. Oncotarget. 7:23885–23896. 2016. View Article : Google Scholar : PubMed/NCBI
|
46
|
Pines J and Rieder CL: Re-staging mitosis:
A contemporary view of mitotic progression. Nat Cell Biol. 3:E3–E6.
2001. View Article : Google Scholar : PubMed/NCBI
|
47
|
Cai K and Dynlacht BD: Activity and nature
of p21(WAF1) complexes during the cell cycle. Proc Natl Acad Sci
USA. 95:12254–12259. 1998. View Article : Google Scholar : PubMed/NCBI
|